Dave Lahr, PhD, is currently leading the computational biology group at Foghorn Therapeutics, a biotech startup focused on treating diseases by correcting abnormal gene expression. In the early days ...

The integration of artificial intelligence (AI) into drug discovery is revolutionizing pharmaceutical research by providing sophisticated tools for understanding and predicting complex biological ...

One might expect that researchers would know how methylphenidate works in the brain by now, but little is known about the drug's mechanism of action. Now, a new study seeks to close this gap and ...

Glovadalen, a novel D1 receptor positive allosteric modulator, is linked to improve OFF time in patients with Parkinson’s ...

Key opinion leaders discuss faricimab, its impact on the treatment landscape for wet AMD/DME, and what payers should look for when considering formulary positioning or utilization-management ...

Late-breaking Phase III data show ianalumab, Novartis’ dual-targeted antibody, reduced disease activity and patient burden in ...

Chemists from the University of Warwick and Monash University have discovered a promising new antibiotic that shows activity ...